Xcelerate Inc (QB) (XCRT) Share Price

Still hasn't been a single word about Xcelerate Inc since Joe died in December?

As the months go by without word from Michael O'Shea it makes people wonder if the sales and marketing director Joe Pignatiello actually handled all the PRs for the company?

Does Mike know how to update shareholders does he know how to post on X or any other platform?

We have gone radio silence since the unfortunate passing of our beloved director?

Is XCRT now a ship without a Captain?


IMO

Don’t say anything but level 2 is looking better!! Because you will get in trouble. Ha. Go Xcrt!!
No no no ... you're not gonna get into trouble .... you're just going to be mocked

Don’t say anything but level 2 is looking better!! Because you will get in trouble. Ha. Go Xcrt!!

Why do you keep showing your average purchase price? 

Oralacles from the past and present seem fos.

Oracles of the past seem
somewhat muted. $0.174 est 2021 ?

Awesome!!!! That says a lot Go Xcrt!!

Share Structure Update. No change! Zero dilution has occurred now for over a year and a half.

https://www.otcmarkets.com/stock/XCRT/security

Not a single word from XCRT since Joe passed away in December?

Who was in charge of news and updates?

Mike doesn't put out a shareholder update after the new year?

I'm continuing to believe that Joe handled all the press for XCRT?

That's marketing right?

Mike you still CEO?

Very shoddy?


IMO

The African community seem to
show 0 interest in this venture ?

The overwhelming interest in
this stock is staggering !

Probably busy doing depostions for Insurance companies?

Seems like running XCRT has only gotten in the way of running forensic research group?

You can stuff them in the same office but seems he can only concentrate on one?

Not XCRT?

IMO

We did not even get a "New year dear shareholders leter " this year.
Unless I missed it.
Still waiting.

Oh well, then there has to be news?

Hopefully it's they found a CEO who is not a part time accountant?

Or full time?

Whatever?


IMO

IMO, NEWS THIS WEEK........

S/S updated this morning. Unchanged. Near 1n1/2 years unchanged.

https://www.otcmarkets.com/stock/XCRT/security

Who dat ?

Has Mike stepped down as CEO yet?


IMO

This is like a party for
professional pallbearers !

Share Structure remains unchanged. Same now for a year and a half.

https://www.otcmarkets.com/stock/XCRT/security

Not a peep out of Xcelerate Inc since Joe Pignatiello died?

Why do you suppose?

Who actually runs this company?

Toxic death spiral?


IMO

$0.174 est 2021,this is worse than a
lower intestinal tract disorder.

4 straight days down after the shoddy paint job Friday?

Remember how gleefull 3rd rate hack promoters were Friday after close trying to paint an idea that something was happening?

Or someone knew something?

Or what it could lead too?

Currently it's led to 4 straight days of PPS decline and probably a 5th day tomorrow?

Hopeful for more paint though Xcelerate Inc is a terrific Friday performer?

IMO

Shareholders deserve a full time CEO? Not a part time accountant?

A full time XCRT might have this POS at .07 right now instead taking it from .13 to .02?

A fake .02?

Fridays paint already drying up?

Does Mike even know he's CEO?

Has he ever been to Tanzania?

Did he intentionally skip out on the Microcap conference?

Shoddy at best?

I'd say walk away Mike but that might of been what you had planned all along?

IMO

S/S update this morning. As has been the case for the past almost year and a half now….. UNCHANGED!!!

https://www.otcmarkets.com/stock/XCRT/security

But,look at how well he did at
the B.F.Borgers incident ?

Part time CEO? Part time forensic accountant or full time Forensic accountant paying no mind as CEO of xcelerate?

How does the board of directors put up with a person moonlighting as a CEO of Xcelerate while doing forensic accounti g for insurance companies out of the same office as Xcelerate?

Why is this acceptable?

Does anyone realize the level of time it takes running investigations into major insurance companies and fraud?

How is a CEO concentrating on his business if all his time is allocated for his other business?

Shareholders deserve better than this? Shareholders do not have stake in forensic accounting company?

They have stake in Xcelerate?

If Mike is still running this forensic accounting out of Xcelerate's office and spend all his time on it the BOD mist act immedialty?

Shareholder value? Does anyone on this board actually care?

IMO

Your posts are getting worse by the day. 

Your fantasies of people putting lotion on themselves. 


Talk about low life 3rd party bashers.

That was a new low even for you.

Joe P and LiarZ could be cousins or family Perhaps? 

Things are starting to add up.

A outstanding job on the forensic part !

https://xcelerate.global/bio/

Psychological disorder much?

XCELERATE DIRECTORS
Michael O'Shea, CEO and Director
Mike O’Shea is a forensic accountant and a licensed private investigator. He has worked closely with such agencies as the Federal Deposit Insurance Corporation, Resolution Trust Corporation, FBI, Office of the Controller of the Currency, US Secret Service and ATF. He has been admitted, on numerous occasions, as an expert witness in forensic accounting in both Federal and State court as well as foreign jurisdictions. He has on several occasions, been appointed as a Receiver by the State Court in South Carolina.

Since 1999, Mike has been the Director of Forensic Research Group, Inc. and has been responsible for implementing and supervising its forensic accounting, financial investigation, and corporate due diligence programs. From 1985-1998 Mike served as Director of Investigations for Investigative Research Group, Inc., a firm that specialized in corporate due diligence, asset searches, bankruptcy review, and loan recovery. The Company had Bank of New York, Chemical Bank, Summit Bancorp, and the New Jersey Economic Authority among its long list of noteworthy clients.

Jason Householder, Director
Jason Householder, Co-Founder and CEO of Charlotte based LenDRgroup Consulting, has more than a decade of experience in the healthcare banking field and specializes in assisting medical, dental, and veterinary practices to devise strategies that run their businesses effectively and achieve peak performance. LenDRgroup has financed over $300mil in practice loans to dentists, physicians, and veterinarians.

Jason has experience helping private practice owners, DSO, MSO, corporations, group practices, and hospital systems improve cash flow and profit margins, pursue expansion, acquire real estate, and devise exit strategies. He ranked as the #1 sales producer seven times when working for Bank of America Practice Solutions, Affinity Bank, and NuGrowrh Solutions

Steve Gravely, Director
Steve Gravely, President of the Consulting Group of Jocassee, Inc, has been responsible for the start-up of 25 manufacturing plants around the world and over 300 new product introductions for large corporations such as Michelin, AT&T, NCR, Fluor/Maruti (India), and General Motors. As the Director of Operations for AT&T’s Global Information Solutions (NCR) for both North American and South America, he was responsible for the operation of manufacturing facilities in Brazil, California, and South Carolina.

Formerly, Steve led a high-level corporate acquisition team in the takeover of the third largest computer operation in Brazil. He also owns the computer industry record for computer R&D Development by designing, testing, and delivering a new PC in just 8 weeks while managing a Business Unit for AT&T. Steve is a graduate of Clemson University with a BS in Industrial Engineering.

XCELERATE ADVISORY BOARD
Dr. Dilan B. Ellegala, MD, FAANS
Dr. Ellegala has been at the forefront of clinical care and medical technology development for two decades. An honors graduate of the University of Washington School of Medicine, he served academic leadership roles as Director of Neurotrauma and Cerebrovascular Neurosurgery at major universities, a founding Dean for Global Health, and has had collaborations with the Wellman Center for Photomedicine at MIT/Harvard, Clemson Bioengineering, and private industry. He has authored over 50 peer reviewed research publications and holds multiple patent claims in ultrasound technology. Dr. Ellegala has successfully commercialized medical technology and applied it to advance clinical care. He has founded several successful medical companies including Sonospine LLC, a pioneer in ultrasonic spine surgery, and a virtual health company recently acquired by AdviNOW, LLC which applies artificial intelligence to healthcare.

Dr. Ellegala has received numerous academic and clinical honors and has been consistently recognized for his excellence in patient care. In addition to his pioneering work in the US, he is a testament to the transformational power of teaching and the ever-present potential for change in the world, as demonstrated through his training of health care workers in remote Tanzania to perform brain and spine surgery. His groundbreaking work in global medical education is documented in the book, “A Surgeon in the Village: An American Doctor Teaches Brain Surgery in Africa”, which was written by Pulitzer-nominated journalist Tony Bartleme. NBC’s Tom Brokaw described the work as “A lyrical, inspirational and altogether rewarding account of first- and third-world surgeons working together to perform neurosurgery miracles in the heart of Africa.”

Dr. Barry Marshall, AC. FRACP, FAA,FRS,MBBS-UWA
Professor Barry Marshall is a Nobel Prize Laureate, Professor of Clinical Microbiology at The University of Western Australia. Professor Marshall (1974 UWA graduate) was awarded the 2005 Nobel Prize for Physiology or Medicine for their discovery of the bacterium Helicobacter pylori (H. pylori) and its role in gastritis and peptic ulcer disease. This discovery has benefited millions of people, maybe saving a million lives over the last 10-20 years.
Professor Marshall returned to Perth and UWA in 1996 after a tenure at the University of Virginia. Today, Professor Marshall is the Director of The Marshall Centre for Infectious Diseases Research and Training, which was founded in his honor. In addition to H. pylori research, the Marshall Centre is at the forefront of infectious disease identification and surveillance, diagnostics and drug design, and transformative discovery.
Professor Marshall has several projects including studying the relationship H. pylori has with the immune system. Recent research has found children with H. pylori are 45 per cent less likely to develop asthma. With this as a basis, Professor Marshall and his team are developing a medication that uses the bacteria to rebalance an overactive immune system and prevent asthma and food allergies.
The Helicobacter pylori Research Group is taking up the challenge to develop new diagnostics and treatments to target H. pylori across the globe. The research team is focused on the prevention, diagnosis and treatment of H. pylori using clinical microbiology, molecular biology, immunology, genomics and systems biology.

Cathy Scangarella
Cathy Scangarella is the Chief Business Development Officer and sector lead for Life Sciences at Choose New Jersey, New Jersey’s leading nonprofit economic development organization. Cathy leads the business development team and oversees the organization’s national and international lead generation, prospect management and business development strategy for all key industries. She also oversees the Choose New Jersey India and Europe offices and has enhanced New Jersey’s relationships with key multipliers and trade associations around the globe.

During her tenure at Choose New Jersey, Cathy developed a new tactical business development approach for business attraction efforts to concentrate efforts in key domestic and international markets. She had a leading role in the strategic planning of Choose New Jersey’s business attraction missions to Israel, Germany, Ireland, and India. While abroad, she helped established international university collaborations and industry partnerships for many of New Jersey’s research universities including Rutgers University, Princeton University, New Jersey City University and Rowan University. Notable clients include Ascelia Pharma, BAP Pharma, CSL Plasma, Fordoz Pharmaceuticals, Minerva Biolabs and Biofarma US.

Cathy is a veteran of New Jersey State government, having served six administrations. With over 25 years of experience in marketing, outreach, and business development, she has served as Deputy Chief of Staff to Lt. Governor Guadagno, Director of State Marketing at the New Jersey Business Action Center, Director of Outreach Programs for Business Retention & Attraction at the New Jersey Economic Development Authority, and Vice President of Marketing & Communications for the New Jersey Commerce Commission. Cathy is a member of the Research With New Jersey Advisory Board, the Innovation New Jersey Coalition, and an E&Y Entrepreneur of the Year Judge 2019-2021. She was named among the ROI-NJ Influencers: Women in Business – Economic Development in 2021.

Cathy holds a Bachelor of Science degree in Business Administration with a concentration in Marketing from Ramapo College of New Jersey. Cathy brings a valued new skill set to our Advisory Board. Cathy’s’ experience business development, along with her years of relationships with research institutions, should prove invaluable to Xcelerate as we begin to advance the development of the portfolio of patents recently acquired from HS Pharmaceuticals as well as our continued development of patentable med-tech.

XCELERATE SCIENCE OFFICER
Dr. Anja Glisovic, Chief Science Officer
Dr. Glisovic received her PhD in X-Ray and Material Physics from Germany’s Georg-August Universitat in 2007. She went on to become the head of the R&D Laboratory, Chief Science Officer, and R&D Project Leader for the Fraunhoffer Institute, the world’s leading applied research organization.

Dr. Glisovic will be bringing her vast experience in scientific research and development, as well as project leadership at the highest levels, to the Xcelerate Team. She holds numerous patents in the fields of medical devices, chemical engineering, and small arms and munitions. Her primary initial responsibility with the Xcelerate will be identifying and developing business combinations and high growth opportunities in the medical arena.

XCELERATE COUNSEL
Andrew I. Telsey, Securities Attorney
Andrew Telsey is an “AV” rated attorney (the highest rating) and has been practicing law in the State of Colorado since 1980. Since 1984, Mr. Telsey has been President and sole shareholder of Andrew I. Telsey, P.C., Centennial, Colorado, a law firm emphasizing securities law, business transactions, mergers and acquisitions, cannabis transactions and general corporate matters for developmental stage and emerging growth companies both nationally and internationally.

Since July 2017, Mr. Telsey has been Of Counsel to the Hoban Law Group, the largest cannabis law firm in the US, where he has been the lead attorney in the securities department.

Mr. Telsey received a Juris Doctor degree from Syracuse University College of Law in 1979 and a Bachelor of Arts degree Magna Cum Laude, from Ithaca College in 1975. He was also named as one of Denver’s Top Lawyers by the Denver Post from 2015-2018.

XCRT appears to be a ship without a Captain?

PPS wise like the Titanic but nothing has happened with XCRT once Joe Pignatiello got sick?

You remember the sales and marketing director who was tied to previously shell who blindsided 3rd party promoters with his status with Xcelerate?

I'm not sure what happened but when he got sick before he passed away, XCRT went silent?

Why? Who was controlling the flow of information?

Is mike still at the helmet?
Was he ever?
Patsy?
Health deteriorating also?

I knew there was a problem when Mike went radio dark after the microcap conference?

This is getting worse by the day?

IMO

Are you saying Caremedx is disgusting or the people who use it?

This is an outlandish claim?

Unprecedented?

Disgusting could be considered as taking a publicly traded company from .13 to .013 but if in fact people who used the product describe it as Disgusting is a much bigger issue?

3rd party hack promoters might want to go on damage control after these new claims?

IMO

Pretty disgusting that you would say  people were rubbing it all over their family members.

Common decency is all we ask for.

Should be ashamed of yourself.

Then again you never are.

Generating revenues on just one of the multi platforms being instituted? Extremely stable share structure which is unheard of in the OTC realm. Low Float. Many shares in tight hands. Next round of updates XCRT will pop nicely. Board is quiet awaiting updates. Hang in there negative Nancy’s 😆🤣😆

XCRT SECURITY DETAILS
Share Structure

Market Cap Market Cap
9,731,592 02/03/2025

Authorized Shares
1,000,000,000 01/30/2025

Outstanding Shares
434,446,072 01/30/2025

Restricted
288,289,635 01/30/2025

Unrestricted
146,156,437 01/30/2025

Held at DTC
123,964,786 01/30/2025

Float
113,254,437 12/31/2023

Par Value
0.0001

I enjoyed when all these slimy 3rd party con promoters started claiming they and their family were all rubbing caremedx all over each other and it miraculously cured them?

Can we get back to that moment?

It was glorious?

IMO

More great reviews-

https://earthsciencebeauty.com/

Great reviews-
https://ceramedx.com/products/restoring-body-lotion

Not a single share added to share count in almost a year and a half!!!! Hard to find…even in OTCQB land.

https://www.otcmarkets.com/stock/XCRT/security

https://www.otcmarkets.com/filing/html?id=17852428&guid=Qb0-kK5UOIxmh3h

https://www.otcmarkets.com/filing/html?id=17485524&guid=Qb0-kK5UOIxmh3h

Great job Mike following up on the empty Friday paint job?

Could of used that moment for an update or to prove you are still even alive?

Unlike the Microcap conference debacle?

But in XCRT fashion let it just dwindle back to obscurity?

All while clowns tell everyone else PPS that go from .13 to .013 is not dilution?

Just dumb luck?

Did the bid ever rise after Fridays horrific paint job?

Who knows?

Glad shareholders have ESN revenue to fall back on? Remember that dynamite buy? 350k for immediate revenue in the millions?

Great business investment by ESN?

IMO

What is just absolutely hilarious is the fact that the average share price has been hovering around the .02’s for most of the past year. Which also coincides with Borgers throwing that nasty money wrench into the mix. Go figure. Ineptitude doesn’t really equal substance. At all in this case!

Go XCRT

Unchanged for almost 1 and 1/2 years now?

Not my opinion NMO!

https://www.otcmarkets.com/stock/XCRT/security

https://www.otcmarkets.com/filing/html?id=17852428&guid=aE0-kKk9hQP2h3h

https://www.otcmarkets.com/filing/html?id=17485524&guid=aE0-kKk9hQP2h3h

Here we go with the "you won't be able to get shares" BS again?

From .13 ro .04 the same people told you not to be left on the sidelines?

The float was drying up?

No dilution?

News and revenues coming?

Strange they all dissapeared when XCRT went into a toxic death spiral and sank 90%?

But all of a sudden they re appear when XCRT does the late Friday paint?

They are back for more selling?

When they are telling to buy you know they are about to dump?


Watch?

IMO

Also, most of the Float is in the hands of folks that are aware of the aforementioned. Won’t be easy to get a large amount of shares under a nickel once Xcelerate starts moving again.

Up 80% on thin air…literally!

Imagine where the share will go on a bullish couple million “shares traded” day. Boomage most likely!

Indeed….

It’s only a matter of time. Patience can be a struggle at times. But I do believe it’ll come to fruition here with Xcelerate here at some point. Waiting game.

If there was a ton of dilution just to keep the lights on (and fluff PR’s) I wouldn’t be here. Which is the case with the vast majority of OTC Tickers. When you read through the Annuals/Semi’s you see where (outside of company expansion issues) everything is self funded? Including extra auditors fees. We know the ESN Group is generating revenue. AfiyaSasa grows some legs XCRT will be off to the races.

Could easily break a dime plus again!

The best is someone didn't fully rise from the dead obviously lol

They claim there's only dilution and selling ...no one is buying..yet now they say phantom sellers ? lolol

I mean it's hard to keep up with BS.


And it's obvious there's no dilution since the updates keep showing us reality.

Nothing like an 80% pop in share price on NO news. And, No volume! Much of the Float (awfully small one at that) is in more patient hands now. Imagine what XCRT/share price will do once we get some news on the good side!

No updates in a while, right along with ZERO dilution? Generating income through the ESN Group. Borgers really put a damper on what they had going on last year. Takes time to clear up all the paperwork involved. So, could be they are working on getting things lined up to move forward.

I sure ain’t going anywhere…regardless of the opines of a couple serious Debbie-Downers😂😂😂😂

No dilution but in the same sentence, phantom sellers drying up?

Total clowns?

These sellers?

Who?

.174 to .013 is dilution?

IMO

Over and over and over again we see there is no dilution here. They update it quire regularly.


So, at some point the sellers dry up and the SP rebounds.

Now we just need some solid updates and we'll be moving north again. jmo


XCRT